Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Partners, LLC

Neither a doctor nor a teaching hospital

Research payments

$380,689

75 payments

Through program year 2025, Clinical Research Partners, LLC is reported as receiving $380,689 in research payments, across 75 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$58,785	22
2024	Research	$70,827	9
2023	Research	$750	2
2022	Research	$1,200	4
2021	Research	$20,605	2
2020	Research	$65,895	15
2019	Research	$162,627	21

Breakdown

Who paid Research payments · program years 2019–2025

Bone Support Inc. $104,022 4 payments
Sanofi US Services Inc. $70,827 9 payments
Hikma Pharmaceuticals USA $53,563 10 payments
VYNE Pharmaceuticals Inc. $42,981 10 payments
Sanofi Pasteur Inc. $38,857 11 payments
Avanir Pharmaceuticals, Inc. $21,805 6 payments
Chugai Pharmaceutical Co., Ltd. $18,749 4 payments
Ironwood Pharmaceuticals, Inc $9,617 7 payments
Lexicon Pharmaceuticals, Inc. $9,188 1 payment
Rhodes Pharmaceuticals L.P. $7,527 3 payments

Studies the money was for Research payments · program years 2019–2025

Biphasic bone graft substitute in revision total hip arthroplasty with significant acetabular bone defects (a retrospective analysis) $104,022 4 payments
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet $67,277 5 payments
Mti-107 $42,981 10 payments
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study $39,836 6 payments
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers $28,978 8 payments
20-Avp-786-306 $21,805 6 payments
Study of DONQ52 in Active Celiac Disease $18,749 4 payments
Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study $13,726 4 payments
A Phase 3, Randomized, Modified Double-Blind, Active-Controlled, Parallel-Group, Lot-to-Lot Consistency, 4-Arm Study to Investigate the Safety and Immunogenicity of A 4-Dose Regimen of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers $9,879 3 payments
Rdea594-401 $9,617 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.